Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for PHIO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -4.035M
March 31, 2026 -4.003M
December 31, 2025 -2.079M
September 30, 2025 -2.085M
June 30, 2025 -2.54M
March 31, 2025 -1.275M
December 31, 2024 -1.371M
September 30, 2024 -1.953M
June 30, 2024 -1.777M
March 31, 2024 -2.011M
December 31, 2023 -2.37M
September 30, 2023 -2.90M
June 30, 2023 -2.771M
March 31, 2023 -2.708M
December 31, 2022 -2.705M
September 30, 2022 -3.526M
June 30, 2022 -2.429M
March 31, 2022 -3.469M
December 31, 2021 -2.471M
September 30, 2021 -3.099M
June 30, 2021 -3.255M
March 31, 2021 -3.033M
December 31, 2020 -2.623M
September 30, 2020 -1.971M
June 30, 2020 -2.032M
Date Value
March 31, 2020 -2.176M
December 31, 2019 -2.546M
September 30, 2019 -1.991M
June 30, 2019 -1.933M
March 31, 2019 -2.175M
December 31, 2018 -1.746M
September 30, 2018 -2.007M
June 30, 2018 -1.86M
March 31, 2018 -1.907M
December 31, 2017 -2.201M
September 30, 2017 -2.197M
June 30, 2017 -2.317M
March 31, 2017 -2.799M
December 31, 2016 -1.372M
September 30, 2016 -1.603M
June 30, 2016 -1.86M
March 31, 2016 -2.925M
December 31, 2015 -1.582M
September 30, 2015 -1.963M
June 30, 2015 -1.80M
March 31, 2015 -1.972M
December 31, 2014 -1.595M
September 30, 2014 -1.766M
June 30, 2014 -2.017M
March 31, 2014 -2.38M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Imunon, Inc. -3.026M
Agenus, Inc. -31.20M
Amgen, Inc. 4.002B
Anika Therapeutics, Inc. -0.684M
BioCryst Pharmaceuticals, Inc. 103.98M

Cash from Operations (Quarterly) Related Metrics